AbbVie announced that its investigational drug etentamig met the dual primary endpoints of objective response rate and progression-free survival in a Phase 3 study for relapsed/refractory multiple myeloma. The results were presented at the 23rd International Myeloma Society Annual Meeting, highlighting significant improvements over standard therapies. AbbVie also showcased other promising treatments in its multiple myeloma portfolio, including trispecific T-cell engager ABBV-2001 and BCL-2 inhibitor surzetoclax. These developments support AbbVie's strategy to address disease complexity and patient needs with innovative therapies.
AbbVie shares trade at USD 263.20 on Pluang as of Sep 17, 2026 19:42 WIB, near their 52-week high of USD 265.97. The stock shows a modest 1-day gain of 0.24%, with a strong buy interest at 86% of order activity. AbbVie’s market cap stands at $463.89 billion, reflecting its significant presence in the health sector.
The FDA has approved a new subcutaneous induction regimen for SKYRIZI (risankizumab-rzaa) to treat adults with moderately to severely active Crohn's disease. This allows patients to start treatment at home using an on-body injector (OBI) device, impr...
Johnson & Johnson reported strong pharmaceutical growth with Innovative Medicine up 7.9%, driving optimism for its stock with a 12-month price target of $288.66, an 11.48% upside. However, its MedTech segment showed weak international sales growth an...
AbbVie announced positive Phase 3 INTREPID study results for lutikizumab, a dual IL-1α/1β antagonist, in treating moderate to severe hidradenitis suppurativa (HS). The study met its primary endpoint with 31.4% of patients achieving HiSCR75 at Week 16...
Retirees are increasingly turning to high-yield dividend stocks from diverse industries to supplement income beyond Social Security's fixed cost-of-living adjustments. Stocks like Verizon, Altria, AbbVie, Realty Income, and Enbridge offer yields from...
AbbVie has partnered with McLaren Racing as an Official Pharmaceutical Partner, launching the Race to Innovate campaign at the 2026 U.S. Grand Prix. For every 10 Constructors' Championship points McLaren earns, AbbVie will donate $10,000 to global ch...
